CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.72−0.02 (-2.35%)
Close on Oct 19, 2026
- Market cap
- $2.68M
- P/E (TTM)
- –
- Dividend yield
- –
Creative Medical Technology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Market Cap | $4.77M | $166.30M |
| Enterprise Value | -$3.92M | $88.19M |
| PS Ratio | 1590.12 | 3.65 |
| PB Ratio | 0.55 | 2.03 |
| P/TBV Ratio | 0.57 | 2.29 |
Enterprise value
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| EV / Sales | -1306.55 | 2.51 |
Income (trailing twelve months)
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Revenue | $3.00K | $58.34M |
| Gross Profit | $2.01K | $105.94M |
| Operating Income | -$6.24M | -$21.40M |
| Pretax Income | -$6.04M | -$14.34M |
| Net Income | -$6.04M | -$22.46M |
| EBITDA | -$6.24M | -$16.91M |
| EPS (Diluted) | -$1.97 | -$0.83 |
Margins
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Gross Margin | 66.9% | 52.9% |
| Operating Margin | -208004.0% | -44.0% |
| Pretax Margin | -201286.0% | -13.3% |
| Profit Margin | -201355.0% | -40.2% |
| EBITDA Margin | -208004.0% | -30.2% |
Returns
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Return on Equity (ROE) | -78.0% | -53.2% |
| Return on Assets (ROA) | -73.3% | -40.9% |
| Return on Invested Capital (ROIC) | -4600.3% | -32.4% |
| Return on Capital Employed (ROCE) | -71.9% | -38.1% |
Growth
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -50.0% | 5.96% |
| Revenue Growth (3Y CAGR) | -59.2% | 2.25% |
| Revenue Growth (5Y CAGR) | -48.4% | 6.48% |
Balance sheet
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $8.71M | $61.43M |
| Net Cash (Debt) | $8.71M | $15.35M |
| Net Cash Per Share | $1.32 | $0.66 |
| Equity (Book Value) | $8.65M | $49.09M |
| Book Value Per Share | $1.31 | $1.37 |
| Tangible Book Value | $8.30M | $23.52M |
| Working Capital | $8.32M | $76.81M |
Financial position
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Current Ratio | 12.91 | 3.34 |
| Quick Ratio | 12.47 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Operating Cash Flow | -$5.90M | -$12.35M |
Efficiency
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.39 |
| Inventory Turnover | 0.02 | 2.70 |
Dividends and yields
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Earnings Yield | -126.6% | -23.3% |
| Buyback Yield | 0.00% | -0.59% |
| Shareholder Yield | 0.00% | 0.00% |
Shares
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Shares Outstanding | 6,592,560 | 58,127,000 |
| Shares Change (YoY) | 65.5% | 10.9% |
| Shares Change (QoQ) | 75.6% | 0.54% |
| Float | 5,545,090 | 49,136,700 |
| Shares Held by Insiders | 15.9% | 11.6% |
| Shares Held by Institutions | 5.65% | 59.4% |
Taxes
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Creative Medical Technology | Industry median |
|---|---|---|
| Altman Z-Score | -8.01 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Creative Medical Technology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.